Skip to main content

Advertisement

Log in

Surgery for pancreatic cancer: critical radiologic findings for clinical decision making

  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States, with an estimated 53,670 new cases diagnosed and an estimated 43,090 deaths in 2017. This high mortality rate is in part due to the small percentage of patients diagnosed with local disease, as well as the biologically aggressive nature of the disease. While only 10–20% of patients will present with surgically resectable disease, this is the only possible curative therapy. Five-year survival of resected pancreatic cancer ranges from 12 to 27%. The National Comprehensive Cancer Network (NCCN) guidelines recommend specific guidelines for imaging modalities used in the diagnosis and staging of pancreatic adenocarcinoma. Indeed, high-quality imaging is not only necessary to accurately stage the disease, but is critical for the determination of key clinical decision branch points such as the determination of surgical resectability. Identification of the lesion within the pancreas, the degree of extra-pancreatic extension, and potential involvement of surrounding vascular structures with the tumor are all findings necessary to classify patients as having resectable, borderline resectable, or with unresectable primary tumors. This article reviews imaging modalities used to evaluate the pancreatic cancer patient from the surgeon’s perspective, with particular emphasis on determination of resectability and preoperative planning, as well as imaging in the postoperative period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig.1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. American Cancer Society. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html (2017).

  2. Ferrone CR, Brennan MF, Gonen M, et al. (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 12(4):701–706

    Article  PubMed  Google Scholar 

  3. Katz MH, Wang H, Fleming JB, et al. (2009) Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 16(4):836–847

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cameron JL, He J (2015) Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 220(4):530–536

    Article  PubMed  Google Scholar 

  5. NCCN Guidelines Version 2.2017 Pancreatic Adenocarcinoma. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. (2017).

  6. Saftoiu A, Vilmann P (2009) Role of endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. J Clin Ultrasound. 37(1):1–17

    Article  PubMed  Google Scholar 

  7. Akita H, Takahashi H, Ohigashi H, et al. (2017) FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Eur J Surg Oncol. 43(6):1061–1067

    Article  CAS  PubMed  Google Scholar 

  8. Asagi A, Ohta K, Nasu J, et al. (2013) Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Pancreas. 42(1):11–19

    Article  PubMed  Google Scholar 

  9. Denbo JW, Fleming JB (2016) Definition and management of borderline resectable pancreatic cancer. Surg Clin North Am. 96(6):1337–1350

    Article  PubMed  Google Scholar 

  10. Tzeng CW, Fleming JB, Lee JE, et al. (2012) Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 19(6):2045–2053

    Article  PubMed  Google Scholar 

  11. Low G, Panu A, Millo N, Leen E (2011) Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. Radiographics. 31(4):993–1015

    Article  PubMed  Google Scholar 

  12. Brennan DD, Zamboni GA, Raptopoulos VD, Kruskal JB (2007) Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiographics. 27(6):1653–1666

    Article  PubMed  Google Scholar 

  13. Mehta VK, Fisher G, Ford JA, et al. (2001) Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg. 5(1):27–35

    Article  CAS  PubMed  Google Scholar 

  14. Katz MH, Marsh R, Herman JM, et al. (2013) Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 20(8):2787–2795

    Article  PubMed  PubMed Central  Google Scholar 

  15. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 13(8):1035–1046

    Article  PubMed  Google Scholar 

  16. Callery MP, Chang KJ, Fishman EK, et al. (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 16(7):1727–1733

    Article  PubMed  Google Scholar 

  17. Mollberg N, Rahbari NN, Koch M, et al. (2011) Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 254(6):882–893

    Article  PubMed  Google Scholar 

  18. Fong ZV, Alvino DML, Fernandez-Del Castillo C, et al. (2017) Reappraisal of staging laparoscopy for patients with pancreatic adenocarcinoma: a contemporary analysis of 1001 patients. Ann Surg Oncol 1:1–9

    Google Scholar 

  19. Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr (2006) The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol. 17(2):189–199

    Article  CAS  PubMed  Google Scholar 

  20. Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGrath D, Fernandez-del Castillo C. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg. 2000;135(4):409–14; discussion 14–5.

  21. Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology. 2014;146(1):291–304 e1.

  22. Brook OR, Brook A, Vollmer CM, et al. (2015) Structured reporting of multiphasic CT for pancreatic cancer: potential effect on staging and surgical planning. Radiology. 274(2):464–472

    Article  PubMed  Google Scholar 

  23. Larson DB, Towbin AJ, Pryor RM, Donnelly LF (2013) Improving consistency in radiology reporting through the use of department-wide standardized structured reporting. Radiology. 267(1):240–250

    Article  PubMed  Google Scholar 

  24. Plumb AA, Grieve FM, Khan SH. Survey of hospital clinicians’ preferences regarding the format of radiology reports. Clin Radiol. 2009;64(4):386–94; 95–6.

  25. Abrams RA, Lowy AM, O’Reilly EM, et al. (2009) Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 16(7):1751–1756

    Article  PubMed  Google Scholar 

  26. de Geus SW, Evans DB, Bliss LA, et al. (2016) Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: a Markov decision analysis. Eur J Surg Oncol. 42(10):1552–1560

    Article  PubMed  Google Scholar 

  27. Katz MH, Fleming JB, Bhosale P, et al. (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 118(23):5749–5756

    Article  PubMed  Google Scholar 

  28. Katz MH, Merchant NB, Brower S, et al. (2011) Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 18(2):337–344

    Article  PubMed  Google Scholar 

  29. Zhou Y, Zhang Z, Liu Y, Li B, Xu D (2012) Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 36(4):884–891

    Article  PubMed  Google Scholar 

  30. Dohan A, Eveno C, Dautry R, et al. (2015) Role and effectiveness of percutaneous arterial embolization in hemodynamically unstable patients with ruptured splanchnic artery pseudoaneurysms. Cardiovasc Intervent Radiol. 38(4):862–870

    Article  PubMed  Google Scholar 

  31. Welsch T, Eisele H, Zschabitz S, et al. (2011) Critical appraisal of the International Study Group of Pancreatic Surgery (ISGPS) consensus definition of postoperative hemorrhage after pancreatoduodenectomy. Langenbecks Arch Surg. 396(6):783–791

    Article  PubMed  Google Scholar 

  32. Zhou TY, Sun JH, Zhang YL, Zhou GH, Nie CH, Zhu TY, et al. Post-pancreaticoduodenectomy hemorrhage: DSA diagnosis and endovascular treatment. Oncotarget. 2017.

  33. Mise Y, Day RW, Vauthey JN, Brudvik KW, Schwarz L, Prakash L, et al. After Pancreatectomy, the “90 Days from Surgery” Definition Is Superior to the “30 Days from Discharge” Definition for Capture of Clinically Relevant Readmissions. J Gastrointest Surg. 2016;20(1):77–84; discussion

  34. Smoot RL, Christein JD, Farnell MB (2006) Durability of portal venous reconstruction following resection during pancreaticoduodenectomy. J Gastrointest Surg. 10(10):1371–1375

    Article  PubMed  Google Scholar 

  35. Zyromski NJ, Howard TJ (2008) Acute superior mesenteric-portal vein thrombosis after pancreaticoduodenectomy: treatment by operative thrombectomy. Surgery. 143(4):566–567

    Article  PubMed  Google Scholar 

  36. Witkowski ER, Smith JK, Ragulin-Coyne E, et al. (2012) Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study. J Gastrointest Surg. 16(1):121–128

    Article  PubMed  Google Scholar 

  37. Tzeng CW, Fleming JB, Lee JE, et al. (2012) Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 14(6):365–372

    Article  PubMed  PubMed Central  Google Scholar 

  38. Tzeng CW, Abbott DE, Cantor SB, et al. (2013) Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 20(7):2197–2203

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Annabelle L. Fonseca.

Ethics declarations

Conflicts of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fonseca, A.L., Fleming, J.B. Surgery for pancreatic cancer: critical radiologic findings for clinical decision making. Abdom Radiol 43, 374–382 (2018). https://doi.org/10.1007/s00261-017-1332-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-017-1332-z

Keywords

Navigation